Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B

Edwards Lifesciences Corp

2021-FY EPS reported $2.38 revenue$5,232,500,000

Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.
Q4 GAAP EPS $0.53; adjusted EPS $0.51.
Full year 2021 sales $5.2B (+19%); adjusted EPS $2.22 (+19% YoY).
FY22 guidance: sales $5.5-6.0B (low double-digit growth); adjusted EPS $2.50-$2.65; Q1 sales $1.27-1.35B.
Completed enrollment of CLASP IID and EARLY TAVR trials; FDA approved SAPIEN 3 with Alterra.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.